May 9 2011
ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today that the Company performed regulatory animal studies treating target vessels with its occlusion system - (EOS) device. The procedures had a 100% success rate in terms of safety and effectiveness.
The device demonstrated accurate, predictable and immediate occlusion of the targeted blood vessels. The EOS device has the potential to address the need for occlusion of vessels in a wide variety of peripheral vascular applications.
The study was performed by a group of physicians from the Johns Hopkins University (Baltimore, MD) and the George Washington University (Washington, DC).
"This study paves the way for the Company's planned First in Man studies scheduled to begin in June as the Company continues the planned execution of its targeted 2011 European commercialization of the EOS device," said Dr. Leon Rudakov, President and CTO, ArtVentive Medical Group, Inc. "We are pleased with the continued compounding success that we have experienced and we look forward to the expansion of our family of EOS devices."
Source:
ArtVentive Medical Group, Inc.